Source: International Congress 2014 – Novel evidence relating to respiratory treatment development
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Kärrman Mårdh, D. Nicholls, I. Dainty, C. Phillips, F. McIntosh (Mölndal, Sweden; Alderley Park, Charnwood, United Kingdom). AZD5069: Pharmacological profile of a CXCR2 antagonist in development for the treatment of respiratory disorders. Eur Respir J 2014; 44: Suppl. 58, 960

Member's Comments

No comment yet.

Related content which might interest you: In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 In vitro profile of the new inhaled pan-JAK inhibitor LAS194046 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Side effects of the leukotriene receptor antagonists in asthmatic children Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Blockade of TSLP pathway alters asthma biomarkers Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 The inverse agonist propranolol does not confer steroid-sparing activity in persistent asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Anti-inflammatory effects of targeted lung denervation in patients with COPD Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Clinical effectiveness of anti-IgE therapy in allergic severe asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Effect of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of AZD5069, an oral CXCR2 antagonist Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics Source: International Congress 2014 – Asthma and COPD management Year: 2014 Expression of CysLT2 receptors in asthmatic lung, and the roles in bronchoconstriction Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Inhibition of JAK/STAT pathway in airway epithelium as a potential targeted therapy of asthma Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Comparison of three modalities of corticosteroids administration in chronic rhinosinusitis Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Therapeutic potential of CPL-407-105 – Novel potent JAK/STAT pathway inhibitor for the treatment of asthma Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 New inhaled JAK inhibitor LAS194046 inhibits allergen-induced airway inflammation in Brown Norway rats Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Effect of the combination of doxofylline and montelukast on LPS-induced leukocyte migration to the lung Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 H4 receptor antagonits as a potential medication for upper airway cough syndrom Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Long-acting anticholinergics in the treatment of severe asthma with irreversible airway obstruction Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014